Clinical trials: H. Pylori Infection
Helicobacter Pylori Infection
Sequential and Hybrid Therapies for H Pylori Infection
Primary: To evaluate efficacy of 14 day 2-phase sequential therapy given in two forms. One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and…
- Trial name
- NCT01085786
- Testing
- 14-day sequential treatment, 14-day hybrid treatment
- Where
- 2 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT02547012
- Testing
- esomeprazole+amox+levo+tetra, esomeprazole+amox+levo
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Peptic Ulcer, Helicobacter Pylori Infection
Clarithromycin Resistant Tailored Therapy
1. Back ground Antibiotics resistance of Helicobacter pylori, especially to clarithromycin is one of the main causes of failure of eradication.
- Trial name
- NCT01453036
- Testing
- 23S rRNA point mutation test of Helicobacter pylori, UBT test & Gastroenterology with biopsy c silver stain
- Where
- South Korea
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Jin Il Kim
H. Pylori Infection
ARJ C13 Urea Breath Test System
An open-label, comparative group study to evaluate the equivalency of the PyloPlus 13C Urea Breath Test to predicate devices on the market.
- Trial name
- NCT04036838
- Testing
- PyloPlus UBT System, Histology, Rapid Urease Test
- Where
- 6 sites in United States
- Volunteers
- 415 people
- Sponsor
- ARJ Medical, Inc.
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
POCone-UBiT-IR300 Pediatric Comparison Study
The purpose of this study is to compare between the POCone® to the UBiT®-IR300 in measuring 13CO2/12CO2 ratio in breath samples when used together with the BreathTek® UBT (urea breath test) Kit and the pUHR-CA web-based software…
- Trial name
- NCT01623154
- Testing
- Pranactin citric solution
- Where
- 3 sites in United States
- Volunteers
- 99 people
- Sponsor
- Otsuka America Pharmaceutical
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy
Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.
- Trial name
- NCT02547038
- Testing
- pantoprazole+bismuth+tetra+metro, (panto+amox+clar+metr)+(panto+amox)
- Where
- Taiwan
- Volunteers
- 352 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Infections
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication.
- Trial name
- NCT00669955
- Testing
- Omeprazole, amoxicillin, clarithromycin, Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
- Where
- United Kingdom
- Volunteers
- 440 people
- Sponsor
- Forest Laboratories
Helicobacter Pylori Infection
Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a first-line regimen for Helicobacter pylori infection…
- Trial name
- NCT04039412
- Testing
- Hybrid regimen, Reverse hybrid regimen, Levofloxacin quadruple regimen
- Where
- Egypt
- Volunteers
- 330 people
- Sponsor
- Ayman Magd Eldin Mohammad Sadek
Helicobacter Pylori Infection
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a…
- Trial name
- NCT04167670
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- 153 sites in United States, Bulgaria and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Suspicion of Being Infected With H.Pylori
Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection
The purpose of this study is to confirm equivalence of a new generation breath analyzer (Modified BreathID) in its ability to detect H. pylori compared to the currently approved BreathID® System.
- Trial name
- NCT01650831
- Testing
- Modified BreathID
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori Infection
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
A phase 4 prospective, randomized, open-label clinical trial evaluating the efficacy of high dose dual therapy vs standard triple therapy in a diverse, urban New York City population.
- Trial name
- NCT05342532
- Testing
- Amoxicillin, Omeprazole, Clarithromycin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
H.Pylori Infection
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in…
- Trial name
- NCT05857163
- Testing
- Rifasutenizol capsules, Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules
- Where
- China
- Volunteers
- 700 people
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infection, Dyspepsia
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp2 (NCT03198507)
- Testing
- RHB-105, Active Comparator
- Where
- 55 sites in United States
- Volunteers
- 455 people
- Sponsor
- RedHill Biopharma Limited
Helicobacter Pylori Infection
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.
- Trial name
- NCT01593592
- Testing
- Lactobacillus reuteri, Omeprazole, Amoxicillin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Zagazig University
Helicobacter Infection
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer.
- Trial name
- 960025 (NCT00656968)
- Testing
- 10-day sequential treatment, 10-day concomitant therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 232 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori
This prospective controlled randomized open-label clinical trial is designed to determine the eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen compared with 7-day standard triple therapy for…
- Trial name
- NCT01575899
- Testing
- Levofloxacin-Amox/clav., Clarithromycin-Amoxicillin
- Where
- Taiwan
- Volunteers
- 208 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed.
- Trial name
- R+OCA (NCT03124199)
- Testing
- Rifaximin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Helicobacter Pylori Infection
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing quadruple therapy was suggested to be the first choice for eradication therapy of Helicobacter pylori in the area with high clarithromycin…
- Trial name
- NCT02541864
- Testing
- Bismuth quadruple therapy, Hybrid therapy
- Volunteers
- 330 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda